Evidence map›Paper›PMID 40152909›Full record

ArticleBrain : a journal of neurology2026

Neuropsychiatric symptoms in sporadic Creutzfeldt-Jakob disease.

Jennifer Zitser, Sven Forner, Katherine Wong, Jin Chengshi, John Neuhaus, Jennifer Martindale, Ben J Raudabaugh, Kendra Benisano, Kelly Goodman-O'Leary, Stacy Metcalf and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain : a journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jennifer ZitserMemory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0003-0200-6185
Sven FornerMemory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Katherine WongMemory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Jin ChengshiDepartment of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA 94158, USA.
John NeuhausDepartment of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA 94158, USA.
Jennifer MartindaleMemory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Ben J RaudabaughMemory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Kendra BenisanoMemory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Kelly Goodman-O'LearyMemory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Stacy MetcalfMemory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Mee-Ohk KimMemory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Marwa HakimiMemory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Isabelle E AllenMemory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Bruce L MillerMemory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Howard J RosenMemory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Katherine P RankinMemory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.
Michael D GeschwindMemory and Aging Center, University of California, San Francisco, San Francisco, CA 94158, USA.

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine P Rankin · 2019 to 2026
$36.9M
PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, BRUCE L · 2004 to 2018
$27.1M
Predicting progression of human prion diseaseR01AG031189 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GESCHWIND, MICHAEL D · 2008 to 2017
$5.7M
Michael J. Homer Family FundNCRR NIH HHSNCRR NIH HHS UL1 RR024131NIA NIH HHS P30 AG062422NIA NIH HHS R01AG031189NIH HHSNINDS NIH HHS N01-NS02328NINDS NIH HHS P01 AG019724NINDS NIH HHS P0 AG010770NINDS NIH HHS P30 AG062422NINDS NIH HHS P50 AG023501
6 · The paper itself

Abstract

Although neuropsychiatric symptoms are not part of diagnostic criteria for sporadic Creutzfeldt-Jakob disease (sCJD), a few retrospective studies and our clinical experience have suggested they are prominent and often occur early. The objective of our study was to assess prospectively the neuropsychiatric features in sCJD (and their impact on caregivers) and compare them with five other neurodegenerative diseases: Alzheimer's disease (AD), dementia with Lewy bodies (DLB), progressive supranuclear palsy, behavioural variant frontotemporal dementia (bvFTD) and semantic variant primary progressive aphasia. The Neuropsychiatric Inventory (NPI) was given at the first UCSF research visit to caregivers of 789 serial patients evaluated at the UCSF Memory and Aging Center from January 2000 through November 2016 who met the diagnostic research criteria for one of these six neurodegenerative disorders. All subjects underwent a Mini-Mental State Examination, and demographic data (age, sex, years of education) were collected. We hypothesized that sCJD has a very prominent behavioural and neuropsychiatric profile, which might help to distinguish it from other neurodegenerative diseases. Of our sCJD cohort (n = 92), 97% exhibited at least one and 50% at least six of the 12 symptoms on the NPI at the time of their first research visit. The most common behavioural symptoms, which occurred in >50% of the sCJD patient cohort, were: appetite/eating disturbances (68%), apathy/indifference (66%), night-time behaviour disturbances (53%), aberrant motor behaviour (53%) and anxiety (52%). Even the least common behaviour, disinhibition, occurred in 19%. Compared with DLB and bvFTD, two conditions with very prominent behavioural features that are included in their diagnostic criteria, sCJD had significantly higher mean NPI frequency × severity scores for night-time behaviour disturbances and delusions. Patients with sCJD scored higher for hallucinations and dysphoria than bvFTD patients and higher for appetite/eating disturbances, aberrant motor behaviour and agitation than patients with DLB. sCJD resulted in significantly worse frequency × severity scores than AD in nine of the NPI symptom domains, with our data revealing sCJD to be a highly behavioural syndrome. No neuropsychiatric symptom is pathognomonic for sCJD, but specific symptoms may enable the differentiation of sCJD from other neurodegenerative diseases. Our findings support the inclusion of behavioural symptoms in sCJD diagnostic criteria.

Indexed as

Creutzfeldt-Jakob SyndromeAgedAged, 80 and overAlzheimer DiseaseFemaleFrontotemporal DementiaHumansLewy Body DiseaseMaleMiddle AgedNeurodegenerative DiseasesNeuropsychological TestsProspective StudiesSupranuclear Palsy, ProgressiveCJDJakob-Creutzfeldt diseasemanagementprion diseasetransmissible spongiform encephalopathy

Identifiers

PMID40152909
PMCPMC12782167

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.